Ser905

Site Information
APRLGSRsQsLSSTD SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 4742258

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:	lung cancer ( 1 , 2 ) , non-small cell lung cancer ( 2 ) , non-small cell lung adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:	293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 3 ) , H2009 (pulmonary) ( 2 ) , H2077 (pulmonary) ( 2 ) , H2887 (pulmonary) ( 2 ) , H322M (pulmonary) ( 2 ) , HOP62 (pulmonary) ( 2 ) , lung ( 1 ) , NCI-H1395 (pulmonary) ( 2 ) , NCI-H2030 (pulmonary) ( 2 ) , NCI-H322 (pulmonary) ( 2 )

Upstream Regulation
Treatments:	angiotensin_2 ( 3 )

References
1	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
2	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
3	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info